Trials / Terminated
TerminatedNCT00234481
Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered Orally to Subjects With Chronic Lymphocytic Leukemia
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of different doses of XL844 when given orally to adults with recurrent or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL844 |
Timeline
- First posted
- 2005-10-07
- Last updated
- 2008-06-04
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00234481. Inclusion in this directory is not an endorsement.